Unichem Laboratories gets USFDA nod for Metronidazole tablets

Shares of the company were trading at Rs 216 per scrip in the afternoon trade, up 0.87%

Press Trust of India New Delhi
Last Updated : Jan 23 2014 | 2:58 PM IST
Unichem Laboratories has received approval from the US Food & Drug Administration to sell generic Metronidazole tablets, an anti-infective agent, in the American market.

The approval is for Metronidazole in strengths of 250 mg and 500 mg, which are therapeutically equivalent to Flagyl Tablets of corresponding strengths of GD Searle LLC, the company said in a filing to the BSE.

The drug is an anti-infective agent used to treat a variety of bacterial and protozoal infections.

Also Read

The product will be commercialised from Unichem's Ghaziabad plant. Active pharmaceutical ingredient Metronidazole used for this ANDA is also made in-house at Roha plant, it said.

At present, around six other companies have generic approvals for the US market and the estimated market size is over $100 million, the company added.

Shares of Unichem Laboratories were trading at Rs 216 per scrip in the afternoon trade, up 0.87 per cent from the previous close, on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 23 2014 | 2:56 PM IST

Next Story